
Opinion|Videos|September 30, 2024
Translating Clinical Data Into the Practice Setting: Monotherapy and Combination Therapies in Intermediate/Poor-Risk mRCC
Author(s)Rana R. McKay, MD
Panelists discuss how the efficacy and safety profiles of various treatment options for intermediate/poor-risk metastatic renal cell carcinoma compare, including cabozantinib monotherapy, nivolumab plus cabozantinib combination, nivolumab plus ipilimumab combination, and other immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations.
Advertisement
Episodes in this series

- Please compare the efficacy and safety in the context of intermediate/poor-risk metastatic renal cell carcinoma:
- Cabozantinib monotherapy
- Nivolumab plus cabozantinib
- Nivolumab plus ipilimumab
- Other immune checkpoint inhibitor plus tyrosine kinase inhibitor combinations
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















